Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of rituximab plus MG4101 in relapsed or refractory indolent CD20-positive non-Hodgkin lymphoma
KCT0003250Phase 2Completed
- Sponsor
- Ministry of Health & Welfare
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, MG4101 in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), Waldenström macroglobulinemia (WM), sponsored by Ministry of Health & Welfare. Started Nov 2018; status: completed.
02
Drugs
rituximabMG4101
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on KCT0003250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003250.